WO2013165898A3 - Compositions et procédés d'inhibition de résolvases - Google Patents
Compositions et procédés d'inhibition de résolvases Download PDFInfo
- Publication number
- WO2013165898A3 WO2013165898A3 PCT/US2013/038650 US2013038650W WO2013165898A3 WO 2013165898 A3 WO2013165898 A3 WO 2013165898A3 US 2013038650 W US2013038650 W US 2013038650W WO 2013165898 A3 WO2013165898 A3 WO 2013165898A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compositions
- resolvases
- inhibiting
- methods
- inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/01—DNA viruses
- G01N2333/065—Poxviridae, e.g. avipoxvirus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L'invention concerne une analyse à base de polarisation de fluorescence (FP) pour identifier des inhibiteurs du clivage d'ADN par une résolvase. L'invention concerne également des inhibiteurs de résolvase identifiés par l'analyse, ainsi que des dérivés et des analogues des inhibiteurs. Les compositions de l'invention peuvent être utilisées pour traiter une infection par un poxvirus.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/397,994 US20150094327A1 (en) | 2012-05-01 | 2013-04-29 | Compositions and methods for inhibiting resolvases |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261640928P | 2012-05-01 | 2012-05-01 | |
US61/640,928 | 2012-05-01 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2013165898A2 WO2013165898A2 (fr) | 2013-11-07 |
WO2013165898A3 true WO2013165898A3 (fr) | 2014-01-16 |
Family
ID=49515015
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2013/038650 WO2013165898A2 (fr) | 2012-05-01 | 2013-04-29 | Compositions et procédés d'inhibition de résolvases |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2013165898A2 (fr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20210106506A (ko) | 2018-12-21 | 2021-08-30 | 셀진 코포레이션 | Ripk2의 티에노피리딘 억제제 |
CN115835909A (zh) | 2020-05-05 | 2023-03-21 | 泰昂治疗公司 | ***素受体2型(cb2)调节剂和其用途 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006071862A2 (fr) * | 2004-12-30 | 2006-07-06 | Takeda Pharmaceutical Company Limited | Polymorphe de 1-(2-methylpropyl)-1h-imidazo[4,5-c][1,5]naphthyridin-4-amine ethanesulfonate |
WO2009008906A2 (fr) * | 2007-02-06 | 2009-01-15 | The Trustees Of The University Of Pennsylvania | Composés thérapeutiques pour un blocage de la synthèse d'adn de poxvirus |
US20100056516A1 (en) * | 2006-07-17 | 2010-03-04 | Williams Peter D | 1-hydroxy naphthyridine compounds as anti-hiv agents |
-
2013
- 2013-04-29 WO PCT/US2013/038650 patent/WO2013165898A2/fr active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006071862A2 (fr) * | 2004-12-30 | 2006-07-06 | Takeda Pharmaceutical Company Limited | Polymorphe de 1-(2-methylpropyl)-1h-imidazo[4,5-c][1,5]naphthyridin-4-amine ethanesulfonate |
US20100056516A1 (en) * | 2006-07-17 | 2010-03-04 | Williams Peter D | 1-hydroxy naphthyridine compounds as anti-hiv agents |
WO2009008906A2 (fr) * | 2007-02-06 | 2009-01-15 | The Trustees Of The University Of Pennsylvania | Composés thérapeutiques pour un blocage de la synthèse d'adn de poxvirus |
Non-Patent Citations (1)
Title |
---|
CULYBA, M ET AL.: "Bulged DNA Substrates For Identifying Poxvirus Resolvase Inhibitors.", NUCLEIC ACIDS RESEARCH, vol. 40, no. 16, 11 May 2012 (2012-05-11), pages E124, Retrieved from the Internet <URL:http://www.ncbi.nlm.nih.gov/pmc/articleslPMC34398751pdf/gks325.pdf> [retrieved on 20131030] * |
Also Published As
Publication number | Publication date |
---|---|
WO2013165898A2 (fr) | 2013-11-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2018236800B2 (en) | DNA-PK inhibitors | |
WO2013163190A8 (fr) | Inhibiteurs d'adn pk | |
TN2013000348A1 (en) | Compounds and compositions as trk inhibitors | |
WO2014028589A3 (fr) | Composés d'acide benzoïque substitués par un 4-hétéroaryle à titre d'inhibiteurs de rorgammat et leurs utilisations | |
MD20140136A2 (ro) | Inhibitori ai virusului hepatic C | |
WO2014153100A3 (fr) | Inhibiteurs de l'arginine méthyltransférase et utilisations de ceux-ci | |
WO2014153235A3 (fr) | Inhibiteurs de l'arginine méthyltransférase et utilisations de ceux-ci | |
GEP201706695B (en) | Substituted 4-phenyl-pyridi-nes for the treatment of nk-1 receptor related diseases | |
EP4219465A3 (fr) | Inhibiteurs de prmt5 et leurs utilisations | |
WO2014028600A3 (fr) | Composés 3-aminocycloalkyl utilisés en tant qu'inhibiteurs de rorgammat et utilisations de ceux-ci | |
MX2015005015A (es) | Inhibidores heteroarilo de pde4. | |
WO2011153157A3 (fr) | Inhibiteurs benzoquinolone de vmat2 | |
EA201590224A1 (ru) | Имидазотриазинкарбонитрилы, используемые в качестве ингибиторов киназы | |
WO2013003298A3 (fr) | Inhibiteurs de pde10 | |
PH12015500211B1 (en) | 4-methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes | |
BR112014028991A2 (pt) | triazóis como inibidores de kv3 | |
WO2014155300A3 (fr) | Dérivés pyrimidine aminée substitués en tant qu'inhibiteurs de tak-1 | |
WO2013057013A3 (fr) | Dérivés d'alcools 1-phényl-2-pyridinylalkyliques utilisés comme inhibiteurs de phosphodiestérase | |
MX2015000980A (es) | Inhibidores de aril lactama cinasa. | |
UA117032C2 (uk) | Селективний інгібітор фосфатидилінозитол-3-кінази-гамма | |
MX2014001604A (es) | Compuestos de antranilamida y sus usos como plaguicidas. | |
AU2015292632B2 (en) | Aldosterone synthase inhibitors | |
MX2014001510A (es) | Compuestos de antranilamida y sus usos como plaguicidas. | |
WO2016164295A3 (fr) | Pyridines fusionnées en tant qu'inhibiteurs de kinase | |
WO2012154879A3 (fr) | Inhibiteurs d'autophagie |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13784316 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14397994 Country of ref document: US |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 13784316 Country of ref document: EP Kind code of ref document: A2 |